A cyclodextrin antibacterial hydrogel that can accelerate wound healing, its preparation method and application

The SD-CS hydrogel, formed through electrostatic interaction, encapsulates pentacyclic triterpenoid compounds, solving the problem of insufficient antibacterial and anti-inflammatory effects of hydrogel dressings and achieving highly efficient wound healing.

CN120478714BActive Publication Date: 2026-11-17HENAN UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510627887.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-05-15
Publication Date
2026-11-17
Estimated Expiration
2045-05-15

AI Technical Summary

Technical Problem

Existing hydrogel dressings have limited antibacterial and anti-inflammatory effects, and pentacyclic triterpenoids are difficult to bind to hydrogels, limiting their application in wound healing.

Method used

A hydrogel was formed by electrostatic interaction between octa-[6-deoxy-(sodium 3-mercaptopropionate)]-γ-cyclodextrin (SD) and chitosan (CS). Pentacyclic triterpenoids were encapsulated in the cavity of SD, and the pH was adjusted to 5.8-6.5 to form a porous hydrogel, which enhanced its antibacterial and anti-inflammatory properties.

Benefits of technology

It improves the water solubility and bioavailability of pentacyclic triterpenoids, enhances the antibacterial and anti-inflammatory properties of hydrogels, promotes cell migration, reduces the expression of inflammatory factors, and significantly accelerates wound healing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120478714B_ABST
    Figure CN120478714B_ABST
Patent Text Reader

Abstract

This invention discloses a cyclodextrin antibacterial hydrogel capable of accelerating wound healing, its preparation method, and its application. The preparation method includes the following steps: mixing a hydrophobic drug with antibacterial and anti-inflammatory effects with a solution of octa-[6-deoxy-(sodium 3-mercaptopropionate)]-γ-cyclodextrin (SD) to obtain a cyclodextrin inclusion complex solution; mixing the cyclodextrin inclusion complex solution with a chitosan (CS) solution to obtain a mixed solution; adding NaHCO3 solution to the mixed solution to adjust the pH to 5.8-6.5, and then allowing it to stand to react, thereby obtaining the cyclodextrin antibacterial hydrogel capable of accelerating wound healing. This invention forms a hydrogel by electrostatic interaction between the anionic compound SD and the cationic polymer CS, while simultaneously loading the hydrophobic drug with antibacterial and anti-inflammatory effects into the cavity of SD, increasing the drug's solubility, improving its bioavailability, and enhancing the antibacterial and anti-inflammatory properties of the hydrogel. The hydrogel of this invention can be used as a wound dressing for bacterial infections, accelerating wound healing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of chemistry and biomedicine, and in particular to a cyclodextrin antibacterial hydrogel that can accelerate wound healing, its preparation method, and its application. Background Technology

[0002] Wound healing is an important and quite complex process involving multiple stages, including hemostasis, inflammation, cell proliferation, and tissue remodeling. Due to the constant exposure of the wound, bacteria can easily invade and colonize it, leading to wound infection of varying degrees. Wound dressings play a crucial role in the clinical treatment of chronic wounds. Hydrogel dressings have received widespread attention in the field of wound repair because they can create a moist microenvironment, promote the exchange of nutrients and metabolites, facilitate cell migration, and ultimately aid wound healing. However, the antibacterial and anti-inflammatory effects of hydrogel dressings themselves are quite limited. Their ability to accelerate wound healing when used alone is also limited.

[0003] To enhance antibacterial and anti-inflammatory properties and further accelerate wound healing, hydrogel dressings can be used in combination with antibacterial drugs. For example, oral antibacterial medication can be administered concurrently with the use of a hydrogel dressing, or a hydrogel dressing can be constructed based on an antibacterial drug. Currently, antibiotic use alleviates bacterial infections to some extent; however, antibiotic use can lead to antibiotic resistance, making wounds more difficult to heal. Pentacyclic triterpenoids and other drugs possess various pharmacological effects, including antibacterial, anti-inflammatory, anti-allergic, and immunomodulatory properties, and can be used as alternatives to antibiotics. However, due to their poor water solubility, low oral bioavailability, significant cytotoxicity at high concentrations, and marked hemolytic effects, their commercial application value is limited. Moreover, because drugs such as pentacyclic triterpenoids have rigid skeletons and strong hydrophobic structures, their molecular structures may contain a lot of nonpolar carbon rings and nonpolar substituents, such as alkyl chains, and lack hydrophilic groups. In contrast, hydrogels are mainly composed of hydrophilic polymer networks and contain a lot of water, so they have many hydrophilic groups, such as hydroxyl, carboxyl, and amino groups. Therefore, it is difficult for drugs such as pentacyclic triterpenoids to bind directly to hydrogels and be encapsulated in hydrogels.

[0004] Therefore, if hydrophobic drugs with antibacterial and anti-inflammatory effects, such as pentacyclic triterpenoids, can be combined with hydrogels to prepare a wound dressing that can effectively accelerate wound healing, it will have great application potential. Summary of the Invention

[0005] The purpose of this invention is to provide a cyclodextrin antibacterial hydrogel capable of accelerating wound healing, its preparation method, and its application, thereby solving the problems existing in the prior art. The cyclodextrin antibacterial hydrogel of this invention, capable of accelerating wound healing, possesses excellent antibacterial properties and good biocompatibility. It can be used as a wound dressing for bacterial infections, effectively inhibiting the inflammatory response of the wound, reducing bacterial infection, and accelerating wound healing.

[0006] To achieve the above objectives, the present invention provides the following solution:

[0007] One of the technical solutions of the present invention: a method for preparing a cyclodextrin antibacterial hydrogel capable of accelerating wound healing, comprising the following steps:

[0008] A hydrophobic drug with antibacterial and anti-inflammatory effects was mixed with a solution of octa-[6-deoxy-(sodium 3-mercaptopropionate)]-γ-cyclodextrin (SD) to obtain a cyclodextrin inclusion complex solution; the cyclodextrin inclusion complex solution was then mixed with a chitosan (CS) solution to obtain a mixed solution; NaHCO3 solution was added to the mixed solution to adjust the pH to 5.8-6.5, and the mixture was allowed to stand for reaction to obtain the cyclodextrin antibacterial hydrogel that can accelerate wound healing.

[0009] Chitosan (CS), a natural cationic polymer, is mainly derived from shrimp and crab shells. It is inexpensive and abundant, possessing excellent biocompatibility, biodegradability, and mucus adhesion. Furthermore, it exhibits various physiological functions, including antibacterial, anticancer, lipid-lowering, and immune-enhancing effects. The outer surface branches of chitosan contain carboxylate groups, giving it a negative overall charge, allowing it to form hydrogels with cationic polymers through electrostatic interactions. This invention combines the anionic compound SD and the cationic polymer CS to form a hydrogel, endowing the hydrogel matrix itself with antibacterial and anti-inflammatory properties. Moreover, the cavity structure of SD allows for the encapsulation of hydrophobic drugs with antibacterial and anti-inflammatory effects. This molecular encapsulation yields a host-guest supramolecular complex with controlled-release properties, thereby improving the water solubility and bioavailability of the hydrophobic drugs and effectively combining the hydrogel with these drugs, thus enhancing the hydrogel's antibacterial and anti-inflammatory properties. When the cyclodextrin antibacterial hydrogel of the present invention, which can accelerate wound healing, is applied to the wounds of mice infected with bacteria, it can inhibit wound inflammation, reduce wound bacterial infection, and thus accelerate wound healing.

[0010] In the preparation method of this invention, adjusting the pH of the mixed solution is to regulate the electrostatic interaction between SD and chitosan, thereby forming a hydrogel with a 3D mesh structure and a porous structure. Furthermore, the inventors have creatively discovered that the successful preparation of a porous hydrogel can only be achieved by adding NaHCO3 solution to adjust the pH of the mixed solution. Using other substances such as sodium phosphate and sodium citrate as pH adjusters, adjusting to the same pH or using the same concentration and amount, fails to achieve the preparation of a porous hydrogel. This may be because the HCO3- in NaHCO3... - It belongs to the monovalent anion and interacts with NH4 in chitosan. + The electrostatic effect is relatively weak, and HCO3 - It can react with H in chitosan solution + This combination allows for pH regulation; however, the anions in sodium phosphate and sodium citrate are polyvalent anions, which will react with NH4+. + The strong Coulomb force binds the molecules together, rapidly neutralizing the charge and causing the molecular chains to aggregate directly, forming a white flocculent precipitate.

[0011] Furthermore, the hydrophobic drug with antibacterial and anti-inflammatory effects is a pentacyclic triterpenoid compound.

[0012] Furthermore, the pentacyclic triterpenoid compounds include glycyrrhizic acid (GL), glycyrrhetinic acid (GA), ursolic acid, or oleanolic acid.

[0013] Furthermore, the mass ratio of the hydrophobic drug with antibacterial and anti-inflammatory effects to the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin contained in the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin solution is 1:1.25-10.

[0014] Furthermore, the mass ratio of octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin in the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin solution to the chitosan in the chitosan solution is 1:5-50.

[0015] Optionally, the concentration of the NaHCO3 solution is 0.6-1.0M.

[0016] Furthermore, the temperature of the static reaction is 0-40℃, and the time is 36-72h.

[0017] Furthermore, the solvent of the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin solution includes water.

[0018] Furthermore, the solvent of the chitosan solution includes an acid solution.

[0019] Furthermore, the concentration of the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin solution is 5-20 mg / mL.

[0020] Furthermore, the concentration of the chitosan solution is 40-60 mg / mL.

[0021] This invention first utilizes octa-[6-deoxy-(sodium 3-mercaptopropionate)]-γ-cyclodextrin to encapsulate hydrophobic drugs with antibacterial and anti-inflammatory effects, obtaining cyclodextrin inclusion complexes. The cyclodextrin inclusion complexes are then mixed with chitosan, and the pH is adjusted using NaHCO3 solution to form a stable hydrogel. The preparation method is simple.

[0022] The second technical solution of the present invention: a cyclodextrin antibacterial hydrogel that can accelerate wound healing prepared by the above-mentioned method for preparing cyclodextrin antibacterial hydrogel that can accelerate wound healing.

[0023] Furthermore, the loading of hydrophobic drugs with antibacterial and anti-inflammatory effects in the cyclodextrin antibacterial hydrogel that can accelerate wound healing is 10-100 μg / mg.

[0024] The loading capacity is defined as: the mass of the hydrophobic drug contained in the cyclodextrin antibacterial hydrogel / the mass of the cyclodextrin antibacterial hydrogel after freeze-drying.

[0025] The third technical solution of the present invention: the application of the above-mentioned cyclodextrin antibacterial hydrogel that can accelerate wound healing in the preparation of drugs or dressings that accelerate wound healing.

[0026] The fourth technical solution of the present invention: a drug or dressing for accelerating wound healing, comprising the above-mentioned cyclodextrin antibacterial hydrogel capable of accelerating wound healing.

[0027] Optionally, the wound-healing medication or dressing may also include pharmaceutically acceptable excipients.

[0028] This invention selects SD with a cavity structure to include pentacyclic triterpenoids. However, not all substances with a cavity structure can achieve the inclusion of pentacyclic triterpenoids. That is, SD in this invention cannot be replaced by other substances with a cavity structure, such as other cyclodextrins.

[0029] Cyclodextrins are a class of substances with a cavity structure, resembling a truncated cone, derived from the chair conformation of the pyranose unit. Hydroxyl groups act on the outer surface of the cavity, with secondary hydroxyl groups located on the wider edge and primary hydroxyl groups on the narrower edge. Within the cavity, hydrogen atoms and glycosidic oxygen atoms form a single bond bridge, giving it lipophilicity. Due to the unique three-dimensional structure of cyclodextrins, its cavity has a hydrophilic exterior and a relatively hydrophobic interior, enabling it to produce water-soluble compounds and to fully or partially encapsulate appropriately sized hydrophobic molecules, thus promoting the formation of inclusion complexes. These inclusion complexes reach dynamic equilibrium in aqueous solutions, characterized by the absence of covalent bonds and defined by stoichiometric subject-guest relationships.

[0030] Cyclodextrins are mainly classified into α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin. Due to the different numbers of glucose units they contain, their cavity diameters and volumes differ, with γ-cyclodextrin having the largest. The basic structure of pentacyclic triterpenoids such as GL consists of a pentacyclic triterpenoid nucleus and a glycosidic group, resulting in a relatively large molecular size. Therefore, the cavity of γ-cyclodextrin is most likely to achieve inclusion of pentacyclic triterpenoids. However, natural γ-cyclodextrin has limited hydrophobic regions and catalytic activity. The strong intramolecular hydrogen bonds formed between the secondary hydroxyl groups reduce the ability of the secondary hydroxyl groups to form hydrogen bonds with surrounding water molecules. Experiments have shown that its actual ability to include pentacyclic triterpenoids is very poor.

[0031] The SD used in this invention is equivalent to replacing the secondary hydroxyl group with sodium deoxy-3-mercaptopropionate while keeping the basic macrocyclic skeleton of cyclodextrin unchanged. This reduces the possibility of intramolecular hydrogen bond formation and forms sodium carboxylate, which increases water solubility.

[0032] The inventors discovered through research that SD is a derivative of γ-cyclodextrin. SD can encapsulate pentacyclic triterpenoids such as GL, while γ-cyclodextrin (γ-CD) cannot, mainly due to the following key differences in molecular design:

[0033] (1) Differences in structural adaptation

[0034]

[0035] Mechanism: SD completely encapsulates the pentacyclic triterpenoid rings and glycosidic groups of pentacyclic triterpenoids such as GL through an expanded cavity, while the γ-CD cavity can only partially accommodate pentacyclic triterpenoid molecules such as GL and cannot bind stably.

[0036] (2) Differences in bonding strength

[0037] Hydrophobic interactions: The thioether chain methyl on the inner wall of the SD cavity forms dense hydrophobic interactions with the hydrophobic surfaces of the pentacyclic triterpenoid nuclei of GL and other pentacyclic triterpenoid compounds, while the hydrophobic interactions of γ-CD are weaker.

[0038] Conformation-induced fit of SD branches can be dynamically adjusted to form a "glove-hand" inclusion, while the rigid structure of γ-CD cannot adapt to the stereoconfiguration of pentacyclic triterpenoids such as GL.

[0039] The present invention discloses the following technical effects:

[0040] This invention forms a hydrogel by electrostatic interaction between anionic compound SD and cationic polymer CS. Simultaneously, a hydrophobic drug with antibacterial and anti-inflammatory effects is loaded into the cavity of SD, increasing drug solubility, improving bioavailability, and enhancing the antibacterial and anti-inflammatory properties of the hydrogel. The hydrogel of this invention not only possesses good antibacterial properties and promotes cell migration while reducing inflammatory factors, but also exhibits good biocompatibility and good, stable mechanical properties.

[0041] The hydrogel of this invention exhibits good antibacterial properties, and the hydrophobic drug with antibacterial and anti-inflammatory effects encapsulated in the SD (scanned medium) can be released sustainably under physiological conditions, effectively improving bioavailability. In vitro cell experiments and erythrocyte hemolysis experiments demonstrated that the hydrogel of this invention has good biocompatibility and promotes the migration of rat fibroblasts (NIH / 3T3) cells. Furthermore, the released natural drug synergistically reduces the expression of inflammatory factors (NO, TNF-α, and IL-6) in raw cells. Application of this hydrogel to bacterial-induced mouse wounds showed that it significantly reduced the number of bacteria in mouse wounds, inhibited the inflammatory response, and accelerated wound healing.

[0042] The hydrogel strategy of this invention can be used to develop novel dressings for treating bacterial infected wounds, which not only has important practical application value in the medical field, but also provides new ideas and possibilities for future research in materials science and biomedicine. Attached Figure Description

[0043] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0044] Figure 1 The images show scanning electron microscope (SEM) images of CS / SD hydrogels prepared under different pH conditions (i.e., with different concentrations of NaHCO3 solution added) in Example 1. In the images, (A), (B), (C), and (D) represent the pH values ​​of the mixed solutions used for gel formation, which are 4.7, 5.8, 6.2, and 6.5, respectively.

[0045] Figure 2Infrared spectra of CS / SD hydrogel and raw materials CS and SD (A), infrared spectra of CS / SD hydrogel and CS / SD / GL hydrogel and raw material GL (B), and ultraviolet-visible absorption spectra of CS / SD hydrogel and CS / SD / GL hydrogel and raw material GL (C).

[0046] Figure 3 The rheological properties of the CS / SD hydrogel obtained by adding 1M NaHCO3 solution are shown in the figures. A represents the dynamic frequency rheological test results, B represents the strain oscillation shear rheological test results, and C represents the cyclic strain rheological test results.

[0047] Figure 4 The diagram shows the process of testing the viscosity and self-healing properties of CS / SD hydrogel. In the diagram, A shows the CS / SD hydrogel inverted in a plastic container, B shows the CS / SD hydrogel placed on a finger joint and bent, CD shows the CS / SD hydrogel being stretched, EF shows the CS / SD hydrogel being stained and placed separately, and G shows the hydrogel being stretched after being bonded together.

[0048] Figure 5 The swelling performance and degradation performance of CS / SD hydrogels obtained by adding 1M NaHCO3 solution are shown in Figure 1. In Figure 2, A represents the swelling performance test result and B represents the degradation performance test result.

[0049] Figure 6 The GL release efficiency curves of the CS / SD / GL hydrogel at different pH values ​​are shown.

[0050] Figure 7 The results of cytotoxicity tests of GL, CS / SD hydrogels and CS / SD / GL hydrogels on RAW 264.7 and NIH / 3T3 cells are shown. Among them, (A) shows the cell viability of RAW 264.7 cells after 24 h of culture, (B) shows the cell viability of RAW 264.7 cells after 48 h of culture, (C) shows the cell viability of NIH / 3T3 cells after 24 h of culture, and (D) shows the cell viability of NIH / 3T3 cells after 48 h of culture.

[0051] Figure 8 Treatment of hemolysis of erythrocytes with water, NaCl, GL, CS / SD hydrogel and CS / SD / GL hydrogel;

[0052] Figure 9The results of in vitro antibacterial effect tests of CS / SD hydrogel and CS / SD / GL hydrogel are shown. Among them, (A) is a colony photograph of S. aurens and E. coli after treatment with different concentrations of CS / SD and CS / SD / GL hydrogel extracts, (B) is a statistical graph of the inhibitory effect on S. aurens, (C) is a statistical graph of the inhibitory effect on E. coli, and (D) is a scanning electron microscope image of bacteria after treatment with different materials.

[0053] Figure 10 The migration of NIH / 3T3 cells at different time points after treatment with different materials;

[0054] Figure 11 The results of the in vitro anti-inflammatory effect test are as follows: (a) RAW264.7 cells in normal growth state (i.e. negative control), (b) RAW264.7 cells after LPS stimulation (i.e. positive control), (c)-(e) RAW264.7 cells after LPS stimulation and treatment with GL, CS / SD, and CS / SD / GL, respectively, and (f)-(h) are the analysis results of NO content, TNF-α content and IL-6 content in cells under the above treatment conditions.

[0055] Figure 12 Photographs (A), wound area and trace analysis (B), and wound healing rate (C) of mice under different treatment groups and at different treatment times;

[0056] Figure 13 Photographs (A) and colony counts (B) of bacteria cultured from the skin around the wounds of mice in different treatment groups at different treatment times;

[0057] Figure 14 The pH changes at the wound site of mice under different treatment groups and at different treatment times;

[0058] Figure 15 H&E staining images of regenerated skin tissue at the wound site of mice under different treatment groups and at different treatment times;

[0059] Figure 16 The results of TNF-α and IL-6 analysis at mouse wound sites under different treatment groups and treatment times are shown. (A) and (C) are the staining results of TNF-α and IL-6, respectively, and (B) and (D) are the content analysis results of TNF-α and IL-6, respectively.

[0060] Figure 17 The staining of α-SMA and CD31 on the skin of mice in different treatment groups on day 14, and the relative fluorescence area of ​​CD31 positivity (B) and α-SMA positivity (C). Detailed Implementation

[0061] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0062] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0063] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0064] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0065] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0066] It should be noted that any aspects not described in detail in this invention are conventional practices in the field and are not the focus of this invention.

[0067] In specific embodiments of the present invention, room temperature or normal temperature refers to 20-30℃.

[0068] Unless otherwise specified, all raw materials used in the specific embodiments of this invention are commercially available products. Among them, the CAS number of octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin (i.e., SD, also known as sugammadextrin sodium) is 343306-79-6, and the degree of deacetylation of chitosan is 90%.

[0069] Example 1

[0070] The preparation steps of CS / SD hydrogel are as follows:

[0071] Accurately weigh 50 mg of SD and dissolve it completely in 5 mL of ultrapure water to obtain an SD solution with a concentration of 10 mg / mL. Dissolve chitosan in 2% (v / v) acetic acid solution to obtain a chitosan solution with a concentration of 50 mg / mL. Take 5 mL of the 50 mg / mL chitosan solution in a beaker, and then slowly add 0.5 mL of the above SD solution. Stir magnetically for 5 hours to mix thoroughly to obtain a mixed solution. Then add 1 mL of 1 M NaHCO3 solution to the above mixed solution to adjust the pH of the mixed solution to 6.5. Then, incubate the pH-adjusted mixed solution at 37°C for 48 hours to obtain CS / SD hydrogel.

[0072] Through the above preparation steps, CS / SD hydrogels with different concentrations of NaHCO3 solution (i.e., different pH values) were obtained by only changing the concentration of NaHCO3 solution (0M, 0.6M, 0.8M, 1.0M, 1.2M, corresponding to pH values ​​of 4.7, 5.8, 6.2, 6.5, 6.7). When the concentration of the added NaHCO3 solution was 0M, the final product was a viscous fluid and hydrogel could not be obtained.

[0073] Figure 1The images show scanning electron microscope (SEM) images of the CS / SD hydrogels prepared under different pH conditions (i.e., with different concentrations of NaHCO3 solution added) in Example 1 (the hydrogels were freeze-dried at -40°C for 48 hours before testing). In the images, (A), (B), (C), and (D) represent the pH values ​​of the mixed solutions used for gel formation as 4.7, 5.8, 6.2, and 6.5, respectively, which correspond to the concentrations of the added NaHCO3 solution as 0 M, 0.6 M, 0.8 M, and 1.0 M. As shown in the figure, when the pH is 4.7 (i.e., without the addition of NaHCO3), the product (viscous fluid) exhibits a layered distribution after freeze-drying. After adjusting the pH with the addition of NaHCO3, the morphology of the product (hydrogel) after freeze-drying gradually changes from a layered distribution to a porous three-dimensional network structure, with cross-linking between the pores. As the concentration of the NaHCO3 solution increases to 1.0M to raise the pH to 6.5, the pore structure gradually becomes more uniform, and the pore size increases. This is beneficial for drug release and allows the product to absorb clotting factors and wound exudate, and deliver metabolites and nutrients when applied to wounds, thus playing an important role in hemostasis and wound healing. Because the concentration of the added NaHCO3 solution was 1.2M, the synthesized hydrogel contained too many bubbles when the pH reached 6.7, and these bubbles were difficult to defoam. Therefore, scanning electron microscopy was not performed on it. The test results show that the pH of the mixed solution between 5.8 and 6.5 (corresponding to the concentration of the added NaHCO3 solution of 0.6-1.0M) is more conducive to obtaining porous CS / SD hydrogels.

[0074] The infrared spectra of the CS / SD hydrogel prepared in Example 1 (with a NaHCO3 solution concentration of 1.0 M) and the raw materials CS and SD are as follows: Figure 2 As shown in (A) in the figure. 3500cm in the figure. -1 The peak at 1652 cm⁻¹ is caused by the stretching vibration of OH groups, and the variation in peak width is due to hydrogen bond interactions. For CS, the peak width is 1652 cm⁻¹. -1 Represents the C=O stretching vibration in acetaminophen (-NHCOCH3), 3469 cm⁻¹ -1 The peak at 3402 cm⁻¹ corresponds to the NH stretching vibration and the OH stretching vibration; for SD, 3402 cm⁻¹ -1 It is an OH stretching vibration, at 1567 cm⁻¹ -1 and 1405cm -1 The absorption peak corresponds to the asymmetric and symmetric stretching vibrations of the carboxylate. When the two react to form a hydrogel, the 3500 cm⁻¹ peak in the figure will be observed. -1 The peak width variation is caused by hydrogen bond interactions. At the same time, the amino group of CS (positively charged) may be electrostatically attracted to the sodium carboxylate of SD (negatively charged), which weakens the peak signal and forms a complex.

[0075] The above results indicate that the CS / SD hydrogel was successfully synthesized.

[0076] Figure 3 The rheological properties of the CS / SD hydrogel obtained by adding 1M NaHCO3 solution are shown. In the figures, A represents the dynamic frequency rheological test results, B represents the strain oscillation shear rheological test results, and C represents the cyclic strain rheological test results (1M in the figures represents the concentration of the added NaHCO3 solution as 1M, G' represents the storage modulus, and G” represents the loss modulus). From... Figure 3 As can be seen from A, when the concentration of the added NaHCO3 solution is 1.0M, the storage modulus (G') is greater than the loss modulus (G”) across the entire frequency range of 0.1-100 rad / s, exhibiting elastic deformation, indicating that the CS / SD hydrogel forms an elastic cross-linked network. Figure 3 As shown in Figure B, when the concentration of the added NaHCO3 solution is 1M, the gel point (intersection of G' and G") is 21.79%. Therefore, the CS / SD hydrogel has appropriate viscoelasticity and can maintain a stable state during daily activities to promote wound healing. The self-healing ability of the CS / SD hydrogel was evaluated using an alternating strain scanning method. After determining the linear viscoelastic range, a strain value of 0.1% was selected within the linear viscoelastic region, and simultaneously, a strain value of 500% after the hydrogel structure collapse was selected for alternating strain scanning. Each scan lasted 100 seconds, and a total of five strain transitions were performed. The results are shown below. Figure 3 As shown in C, when the concentration of the added NaHCO3 solution is 1.0M, G' and G” of the CS / SD hydrogel can still recover to their initial state after 5 cycles, which proves that the CS / SD hydrogel has the ability to self-repair after fracture and that the CS / SD hydrogel structure is relatively stable. Figure 4 The adhesiveness and self-healing properties of the CS / SD hydrogel were further demonstrated. A shows that the CS / SD hydrogel adheres to the bottom of an inverted plastic container without falling off, indicating good adhesiveness. B shows that when the CS / SD hydrogel is placed on a finger joint, it maintains excellent adhesiveness and does not detach with joint movement even when the joint is bent at 90°. CD shows that when the CS / SD hydrogel is stretched, it deforms but does not break. EF shows that after staining the freshly prepared CS / SD hydrogel with Rhodamine and Coomassie Brilliant Blue and then placing them separately, the boundary between the two CS / SD hydrogels disappears after a period of time, indicating that the two CS / SD hydrogels have merged. G shows that when the merged hydrogel in E is stretched with tweezers, the hydrogel does not break at the boundary, indicating that the CS / SD hydrogel has good self-healing properties.

[0077] The swelling and degradation properties of CS / SD hydrogels obtained by adding 1M NaHCO3 solution were tested. The specific procedures were as follows: swelling performance was tested using freeze-dried hydrogels (-40℃, 48h), and degradation performance was tested using freshly prepared hydrogels. The hydrogels were placed in PBS solutions at room temperature and different pH values ​​(5.0, 7.0, 8.3). At regular intervals, the hydrogels were removed, their surfaces dried with filter paper, and their weight measured. They were then returned to the solutions until equilibrium was reached or a certain time was elapsed. The swelling rate and degradation rate of the hydrogels were calculated. The test results are as follows: Figure 5 As shown in the figure, A represents the swelling performance test results, and B represents the degradation performance test results. It can be seen that the generated CS / SD hydrogel has good swelling performance, with the highest swelling rate (400%) in PBS solution at pH 7.4 and the lowest swelling rate in PBS solution at pH 5.0. This may be related to the pH value at which the CS / SD hydrogel is formed. Simultaneously, the CS / SD hydrogel degrades most in PBS solution at pH 5.0, possibly because the cross-linking density of the CS / SD hydrogel is lower at pH 5.0, resulting in a faster degradation rate. Therefore, this CS / SD hydrogel possesses good degradation ability and can respond to the slightly acidic environment of the wound site, meeting the requirements for novel wound dressings.

[0078] Example 2

[0079] The preparation steps of the cyclodextrin antibacterial hydrogel (i.e., CS / SD hydrogel loaded with GL) that can accelerate wound healing are as follows:

[0080] Accurately weigh 50 mg of SD and dissolve it completely in 5 mL of ultrapure water to obtain an SD solution. Then accurately weigh 40 mg of GL and add it to the above SD solution, stirring thoroughly to dissolve, obtaining an SD / GL solution with a GL concentration of 8 mg / mL (i.e., a cyclodextrin inclusion complex solution). Dissolve chitosan in 2% (v / v) acetic acid solution to obtain a chitosan solution with a concentration of 50 mg / mL. Take 5 mL of the 50 mg / mL chitosan solution in a beaker, and then slowly add 0.5 mL of the above SD / GL solution, stirring magnetically for 5 hours to mix evenly, obtaining a mixed solution. Then add 1 M NaHCO3 solution to the above mixed solution until the pH value of the mixed solution is 6.5, and then let the pH-adjusted mixed solution stand at 37°C for 48 hours to obtain a GL-loaded CS / SD hydrogel, denoted as CS / SD / GL hydrogel. The prepared CS / SD / GL hydrogel was washed three times with distilled water to remove the free GL adhering to the surface of the hydrogel. The concentration of free GL in the solution was then measured by UV-Vis spectrophotometry to calculate the mass of GL loaded into the hydrogel. Combined with the mass of the hydrogel after freeze-drying (-40℃, 48h), the loading amount of GL in the hydrogel was calculated to be 13.8 μg / mg.

[0081] Figure 2 (B) shows the infrared spectra of the CS / SD hydrogel prepared in Example 1 (with a NaHCO3 solution concentration of 1.0 M), the CS / SD / GL hydrogel prepared in Example 2, and the raw material GL. For GL, 1729 cm⁻¹ -1 and 1652cm -1 The peak at 3500 cm⁻¹ represents the carboxyl and carbonyl groups in GL. -1 The change in peak width at that point may be caused by hydrogen bond interactions. Figure 2 In Figure (C), the UV-Vis absorption spectra of the CS / SD hydrogel prepared in Example 1 (with a NaHCO3 solution concentration of 1.0 M), the CS / SD / GL hydrogel prepared in Example 2, and the raw material GL in the 200-500 nm range are shown. As can be seen from the figure, the absorption peak of GL is at 257 nm, while the CS / SD hydrogel does not show an absorption peak at this point. However, when GL is loaded onto the CS / SD hydrogel, a characteristic peak appears at 275 nm. Therefore, it can be seen that GL was successfully loaded into the CS / SD hydrogel, proving the successful synthesis of the CS / SD / GL hydrogel.

[0082] Example 3

[0083] The preparation steps of a cyclodextrin antibacterial hydrogel capable of accelerating wound healing (i.e., a CS / SD hydrogel loaded with glycyrrhetinic acid) are as follows:

[0084] Accurately weigh 50 mg of SD and dissolve it completely in 5 mL of ultrapure water to obtain an SD solution. Then accurately weigh 10 mg of glycyrrhetinic acid (GA) and add it to the above SD solution. Stir thoroughly to dissolve, obtaining an SD / GA solution with a GA concentration of 2 mg / mL (i.e., a cyclodextrin inclusion complex solution). Dissolve chitosan in 2% (v / v) acetic acid solution to obtain a chitosan solution with a concentration of 50 mg / mL. Take 5 mL of the 50 mg / mL chitosan solution in a beaker, and then slowly add 0.5 mL of the above SD / GA solution. Stir magnetically for 5 hours to mix evenly, obtaining a mixed solution. Then add 1 M NaHCO3 solution to the above mixed solution until the pH value of the mixed solution is 6.5. Then, incubate the pH-adjusted mixed solution at 37°C for 48 hours to obtain a GA-loaded CS / SD hydrogel, denoted as CS / SD / GA hydrogel. The loading of GA in the hydrogel was tested and calculated to be 17 μg / mg.

[0085] Comparative Example 1

[0086] Accurately weigh 50 mg of SD and dissolve it completely in 5 mL of ultrapure water to obtain an SD solution with a concentration of 10 mg / mL. Dissolve chitosan in 2% (v / v) acetic acid solution to obtain a chitosan solution with a concentration of 50 mg / mL. Take 5 mL of the 50 mg / mL chitosan solution in a beaker, and then slowly add 0.5 mL of the above SD solution. Stir magnetically for 5 hours to mix thoroughly to obtain a mixed solution. Then add 1 M sodium citrate solution to the above mixed solution. When the 1 M sodium citrate solution is added dropwise, flocculent matter immediately appears in the mixed solution, and a hydrogel cannot be obtained.

[0087] Comparative Example 2

[0088] Accurately weigh 50 mg of SD and dissolve it completely in 5 mL of ultrapure water to obtain an SD solution with a concentration of 10 mg / mL. Dissolve chitosan in 2% (v / v) acetic acid solution to obtain a chitosan solution with a concentration of 50 mg / mL. Take 5 mL of the 50 mg / mL chitosan solution into a beaker, and then slowly add 0.5 mL of the above SD solution. Stir magnetically for 5 hours to mix thoroughly to obtain a mixed solution. Then add 1 M sodium phosphate solution to the above mixed solution until the pH of the mixed solution is 6.5. Then, let the mixed solution stand at 37°C for 48 hours. As a result, flocculent matter appeared in the mixed solution, and a hydrogel could not be obtained.

[0089] Comparative Example 3

[0090] Accurately weigh 50 mg of γ-CD and dissolve it completely in 5 mL of ultrapure water to obtain a γ-CD solution with a concentration of 10 mg / mL. Dissolve chitosan in 2% (v / v) acetic acid solution to obtain a chitosan solution with a concentration of 50 mg / mL. Take 5 mL of the 50 mg / mL chitosan solution in a beaker, and then slowly add 0.5 mL of the above γ-CD solution. Stir magnetically for 5 hours to mix thoroughly to obtain a mixed solution. Then add 1 M NaHCO3 solution to the above mixed solution until the pH of the mixed solution is 6.5. Then, let the mixed solution stand at 37°C for 48 hours. As a result, flocculent matter appeared in the mixed solution, and a hydrogel could not be obtained.

[0091] In addition, 50 mg of γ-CD was accurately weighed and dissolved thoroughly in 5 mL of ultrapure water to obtain a γ-CD solution. Then, 10 mg of GL was accurately weighed and added to the above SD solution. After thorough stirring, it was found that very little GL dissolved, indicating that the γ-CD contained very little GL and could not effectively improve the solubility of GL. This shows that replacing SD with γ-CD failed to form a hydrogel and also failed to achieve effective GL encapsulation.

[0092] Comparative Example 4

[0093] Accurately weigh 50 mg of sulfobutyl-β-cyclodextrin (SBE-β-CD) and dissolve it completely in 5 mL of ultrapure water to obtain an SBE-β-CD solution with a concentration of 10 mg / mL. Dissolve chitosan in 2% (v / v) acetic acid solution to obtain a chitosan solution with a concentration of 50 mg / mL. Take 5 mL of the 50 mg / mL chitosan solution into a beaker, and then slowly add 0.5 mL of the above SBE-β-CD solution. Stir magnetically for 5 hours to mix thoroughly to obtain a mixed solution. Then add 1 M NaHCO3 solution to the above mixed solution until the pH of the mixed solution is 6.5. Then, let the mixed solution stand at 37 °C for 48 hours to obtain CS / SBE-β-CD hydrogel.

[0094] In addition, 50 mg of SBE-β-CD was accurately weighed and dissolved thoroughly in 5 mL of ultrapure water to obtain an SBE-β-CD solution. Then, 10 mg of GL was accurately weighed and added to the above SBE-β-CD solution. After thorough stirring, it was found that very little GL dissolved, indicating that the SBE-β-CD loaded very little GL, failing to effectively improve the solubility of GL. This suggests that although replacing SD with SBE-β-CD can form a hydrogel, it cannot effectively encapsulate GL. That is, the sulfobutyl-β-cyclodextrin in the CS / SBE-β-CD hydrogel has a negligible effect on encapsulating small molecule hydrophobic drugs such as GL, resulting in a very low drug loading and poor performance in later use.

[0095] Test Example 1

[0096] The CS / SD / GL hydrogel prepared in Example 2 was subjected to an in vitro GL release test. The test method was as follows: 5.0 g of CS / SD / GL hydrogel was placed in 15 mL of PBS solution with pH values ​​of 5.0, 7.4, and 8.3, respectively. The solution was shaken at 37°C and 200 rpm. At regular intervals, 3 mL of solution was taken out to detect the amount of GL released. Then, 3 mL of PBS solution with the same pH value was added to maintain a constant total volume of the release solution. The amount of GL released was measured using a UV spectrophotometer. The test results are as follows. Figure 6 As shown in the release curves, GL can be rapidly released within 12 hours, after which the release slows down and gradually reaches equilibrium. In the first 8 hours, the release rate of the CS / SD / GL hydrogel under acidic pH 5.0 conditions is higher than that under pH 7.4 and 8.3. By 12 hours, the final release amounts of all three reach 60%, with the release amount under weakly acidic conditions being higher than that under neutral and weakly alkaline conditions. This may be because the hydrogel degrades faster under acidic conditions, which facilitates the rapid release of GL molecules from the hydrogel, thus accelerating drug release. The results indicate that the construction of the gel-loaded drug delivery system can prolong the drug's action time, achieving a continuous drug delivery effect and overcoming the disadvantages of frequent drug administration. The prepared CS / SD / GL hydrogel drug delivery system achieves the expected release effect under simulated wound conditions, showing promising application prospects in the field of wound healing drug delivery.

[0097] Example 1 of effect verification

[0098] Cytotoxicity test

[0099] Cytotoxicity is an important issue in the application of antibacterial hydrogels. The MTT assay was used to determine the cytotoxicity of GL, CS / SD hydrogels (with 1.0 M NaHCO3 solution added), and CS / SD / GL hydrogels against RAW 264.7 and NIH / 3T3 cells. Specifically, NIH / 3T3 and RAW 264.7 cells were cultured to the logarithmic growth phase, and then... (The sentence is incomplete and requires more context to translate accurately.) 3Cells were seeded into 96-well plates. After cell adhesion, 100 μL of different concentrations of free GL solution (25 μg / mL, 50 μg / mL, 75 μg / mL, 100 μg / mL, PBS as solvent) or CS / SD / GL hydrogel extract with an equal GL concentration (obtained by extracting the CS / SD / GL hydrogel prepared in Example 2 in PBS at room temperature for 24 h, by changing the mass of the CS / SD / GL hydrogel and the volume of PBS to achieve a GL concentration in the CS / SD / GL hydrogel of 25 μg / mL, 50 μg / mL, 75 μg / mL, 100 μg / mL, respectively) or different concentrations of CS / SD / GL hydrogel extract were added. The gel extraction buffer (obtained by extracting CS / SD hydrogel in PBS at room temperature for 24 h, wherein the concentrations of CS / SD hydrogel extraction buffer (25 μg / mL, 50 μg / mL, 75 μg / mL, and 100 μg / mL) represent the concentrations of CS / SD hydrogel in PBS solvent, respectively, which are the same as the concentrations of the hydrogel carrier portion in CS / SD / GL hydrogel extraction buffers with an equivalent GL concentration of 25 μg / mL, 50 μg / mL, 75 μg / mL, and 100 μg / mL) were used. After culturing for 24 h or 48 h, 20 μL of 5 mg / mL MTT solution was added, and the cells were cultured for another 4 h. The supernatant was discarded, and 150 μL of LDMSO was added to dissolve and crystallize the cells. Finally, the OD value at 492 nm was measured using a microplate reader, and cell viability was calculated. Results are as follows: Figure 7As shown, (A) represents cell viability after 24 hours of RAW 264.7 culture, (B) represents cell viability after 48 hours of RAW 264.7 culture, (C) represents cell viability after 24 hours of NIH / 3T3 culture, and (D) represents cell viability after 48 hours of NIH / 3T3 culture. It can be seen that after co-culturing RAW 264.7 and NIH / 3T3 cells with GL, CS / SD, and CS / SD / GL hydrogels for 24 hours and 48 hours respectively, both cell types showed good viability, exceeding 100%, even at a concentration of 100 μg / mL, promoting cell proliferation. This indicates that CS / SD and CS / SD / GL hydrogels have good biocompatibility with these two cell types, laying the foundation for their application in wound healing. Hydrogel wound dressings come into direct contact with red blood cells during application; therefore, studying the blood-related properties of hydrogel materials is crucial. Using deionized water as a positive control and 0.9 wt% NaCl solution as a negative control, 50 μg / mL of free GL solution, CS / SD / GL extract loaded with an equal volume of GL, and 50 μg / mL of CS / SD extract (the preparation methods and concentrations of CS / SD / GL extracts are the same as above) were co-incubated with erythrocytes for 4 h. The hemolysis status of erythrocytes treated in different experimental groups was as follows: Figure 8 As shown in the results, the hemolysis rates of GL, CS / SD hydrogels, and CS / SD / GL hydrogels were 2.39%, 1.79%, and 1.49%, respectively, all below the international standard of 5%. Therefore, both CS / SD and CS / SD / GL hydrogels exhibit good blood compatibility and show significant application value in biomedical fields such as hemostasis and skin regeneration. The reason why CS / SD / GL hydrogel can effectively reduce the hemolysis rate may be that after SD encapsulates GL, it forms a hydrogel with chitosan, giving it a sustained-release function. In other words, the hydrogel does not cause a burst release of GL, resulting in an excessively high local concentration of GL, thus reducing its toxicity. Furthermore, the slow release prolongs the time for GL to exert its effect, improving the drug's efficacy.

[0100] Example 2 of effect verification

[0101] (1) In vitro antibacterial effect of hydrogel

[0102] Wound infections are characterized by the proliferation of bacteria in living tissue. These bacteria damage the tissue and hinder wound healing; therefore, the primary function of wound dressings is antibacterial efficacy. The in vitro antibacterial effects of CS / SD hydrogel (with 1.0M NaHCO3 solution) and CS / SD / GL hydrogel were investigated using a plate count method. Specifically, in a clean bench, a single colony was picked up with a disposable inoculation loop and placed in PBS. The colony was then evenly dispersed and serially diluted with PBS. Finally, the colony concentration was determined to be 2 × 10⁻⁶ using a plate count method. 7 CFU / mL. Take 50 μL of the diluted bacterial suspension and add different concentrations of hydrogel extraction buffer (the preparation method and meaning of the concentration are the same as above) or GL solution to a final volume of 500 μL. Co-incubate at 37℃ for 30 min. Then, take 100 μL of the cultured bacterial suspension and spread it on a culture plate, incubating at 37℃ for 18 h. Finally, record the colony count and calculate the inhibition rate. Results are as follows... Figure 9 As shown, (A) are colony photographs of *S. aureus* and *E. coli* after treatment with different concentrations of CS / SD and CS / SD / GL hydrogel extracts; (B) is a statistical graph of the inhibitory effect on *S. aureus*; (C) is a statistical graph of the inhibitory effect on *E. coli*; and (D) are scanning electron microscope images of bacteria after treatment with different materials. The normal group of bacteria was treated with PBS, the GL group with a free GL solution at a concentration of 1 mg / mL, and the CS / SD / GL and CS / SD groups were treated with extracts at a concentration of 50 μg / mL (the preparation methods and concentrations of the CS / SD / GL and CS / SD extracts are the same as above). Figure 9As shown, after co-culturing *S. aurens* and *E. coli* with different concentrations of CS / SD and CS / SD / GL hydrogel extracts for 30 min, the antibacterial effect of the hydrogels against *S. aurens* and *E. coli* gradually increased with increasing concentrations of CS / SD and CS / SD / GL hydrogels. CS / SD hydrogels showed no antibacterial effect against *S. aurens* at concentrations below 10 μg / mL, but achieved a 60% antibacterial effect against *E. coli*. At a concentration of 35 μg / mL, the antibacterial effects against *S. aurens* and *E. coli* reached 90% and 100%, respectively. When GL was loaded onto CS / SD hydrogels, the CS / SD / GL hydrogel exhibited a stronger antibacterial effect. This indicates that the combined effect of GL and CS / SD hydrogels gives the hydrogels stronger antibacterial activity. Furthermore, after treatment with CS / SD hydrogel and CS / SD / GL, Staphylococcus aureus was destroyed, exhibiting shrinkage and deformation; Escherichia coli cell membranes were severely deformed and indented, making bacterial growth difficult. These morphological changes demonstrate that CS / SD hydrogel and CS / SD / GL hydrogel can kill bacteria, exhibiting superior antibacterial effects.

[0103] (2) Hydrogels promote cell migration in vitro

[0104] NIH / 3T3 cells in logarithmic growth phase were harvested at a density of 2 × 10⁶ cells per well. 5 Cells were seeded at a density of 100 μL in six-well plates. After confluence, the cells were marked with a marker and then vertically marked with a 200 μL sterile pipette tip. The old culture medium was removed, and the cells were washed with PBS until clean. The normal group (Normal) was cultured in medium containing 10 wt% serum, and the control group (Control) was cultured in medium containing 2 wt% serum. The experimental groups were cultured with 100 μL of 50 μg / mL free GL solution, CS / SD / GL extract, and CS / SD hydrogel extract (the preparation method and concentration of the extracts are the same as above). Cells were cultured in 2 wt% serum medium for 12 h and 24 h, respectively. Cell migration was observed under a microscope and photographed. The effects of GL, CS / SD hydrogel (with added NaHCO3 solution at a concentration of 1.0 M), and CS / SD / GL hydrogel on NIH / 3T3 cell migration are as follows: Figure 10As shown, the scratches in each group gradually narrowed over time, indicating that GL, CS / SD, and CS / SD / GL hydrogels all promoted cell migration. Compared to the control group, cells migrated rapidly after 12 hours of treatment with CS / SD and CS / SD / GL hydrogels, respectively, with a higher migration rate than the GL-treated group. Scratch healing was more pronounced after 24 hours. Compared to the normal group, the CS / SD and CS / SD / GL hydrogels achieved the same cell migration promotion effect, with CS / SD / GL hydrogel showing a slight advantage over CS / SD hydrogel. This suggests that the released GL synergistically accelerates the migration of fibroblasts (NIH / 3T3 cells) to the scratch area in conjunction with CS / SD hydrogel, and also promotes cell proliferation.

[0105] (3) In vitro anti-inflammatory effect of hydrogel

[0106] RAW 264.7 cells in good growth condition were seeded at a density of 3 × 10⁶ cells per well. 5 Cells were seeded at a density of [number] cells per well in six-well plates. After cell attachment, they were cultured for 4 hours in DMEM high-glucose medium containing 50 μg / mL free GL, CS / SD / GL hydrogel with an equal GL loading concentration, or 50 μg / mL CS / SD hydrogel (with 1.0 M NaHCO3 solution added) (concentration meanings are the same as above). LPS was then added to a final concentration of 1 μg / mL, and the cells were cultured for another 24 hours. Cells cultured in DMEM high-glucose medium without drugs and LPS served as negative controls, while cells cultured with LPS but without drugs served as positive controls. Finally, cell morphology was observed, and the cell supernatant was used to detect the levels of NO, TNF-α, and IL-6 in RAW 264.7 cells using an ELISA kit. The results are shown below. Figure 11 As shown.

[0107] The second stage of wound healing is the inflammatory phase. Inflammation plays a crucial role in regulating the wound healing process. In infected wounds, bacterial invasion and the release of pro-inflammatory cytokines such as interleukin-1-β and tissue necrosis factor-α inhibit fibroblast activity, leading to an increase in matrix metalloproteinases (MMPs), thereby reducing the production of growth factors and ultimately preventing them from entering the proliferation phase. Therefore, detecting the expression of pro-inflammatory cytokines TNF-α, IL-6, and NO is used to demonstrate the anti-inflammatory ability of the hydrogel. Figure 11As shown, (a) are RAW 264.7 cells in normal growth state (i.e., negative control), where cells are observed to grow in round aggregates adhering to the cell wall. (b) are RAW 264.7 cells after LPS stimulation (i.e., positive control), where cells are observed to enlarge and develop tentacles, indicating successful cell modeling. (c)-(e) are RAW 264.7 cells after LPS stimulation followed by the addition of GL, CS / SD, and CS / SD / GL, respectively. It is evident that when RAW 264.7 cells are co-cultured with GL, CS / SD, or CS / SD / GL and LPS, the number of tentacles decreases, and some cells become round, gradually restoring the normal morphology of RAW 264.7 cells. This demonstrates that GL, CS / SD, and CS / SD / GL can effectively inhibit cell differentiation and alleviate inflammatory responses. The NO content in the cell supernatant of each group was measured, and the results are as follows. Figure 11 As shown in (f), compared with the LPS group (170.48 μM), the NO levels after treatment with GL, CS / SD, and CS / SD / GL were 62.78 μM, 53.14 μM, and 43.96 μM, respectively, effectively inhibiting NO secretion. The TNF-α and IL-6 levels obtained from the cell supernatants were detected using an ELISA kit, as shown in (f). Figure 11 As shown in (g) and (h), after stimulation of RAW 264.7 cells with LPS, the secretion of TNF-α and IL-6 in the LPS group (i.e., the positive control group) was significantly higher than that in the negative control group (i.e., the Normal group). After treatment with GL, CS / SD, and CS / SD / GL hydrogels, the contents of TNF-α and IL-6 decreased. Among them, the CS / SD / GL hydrogel had the best inhibitory effect on TNF-α and IL-6, indicating that the CS / SD / GL hydrogel showed a stronger anti-inflammatory effect due to the addition of GL.

[0108] (4) Effect of hydrogel on promoting wound healing in mice in vivo

[0109] The therapeutic effect of hydrogel on mouse wounds was evaluated using a Staphylococcus aureus-infected skin wound model. After one week of acclimatization feeding, the fur on the backs of KM mice was removed. The mice were anesthetized, and a circular full-thickness skin wound with a diameter of 7 mm was created on the back using a punch. Then, 50 μL of a 2×10⁻⁶ hydrogel was applied. 8Staphylococcus aureus culture at CFU / mL was used. After absorption, the culture was fixed with medical gauze and medical tape. After 24 hours of incubation, redness and purulent discharge at the wound site indicated successful model establishment. Mice were randomly divided into 5 groups (n=10 per group). Group 1 was a positive control, treated with commercially available medical hydrogel wound dressing (ofloxacin hydrogel, Wanchuan Pharmaceutical). Group 2 was a negative control (treated with 0.9wt% saline, no other treatment). Group 3 was treated with GL PBS solution (50 μg / mL). Group 4 was treated with CS / SD hydrogel dressing prepared in Example 1 (with 1.0M NaHCO3 solution added). Group 5 was treated with CS / SD / GL hydrogel dressing prepared in Example 2. The amount of hydrogel used in Groups 1, 4, and 5 was the same each time. All groups had normal drinking and feeding, and the dressings were changed every 48 hours.

[0110] The wounds on the backs of mice were photographed at days 0, 3, 7, 10, and 14 to record the healing rate. The wound healing photos and healing rates are shown below. Figure 12 As shown in the figure, (A) are photographs of mouse wounds treated with different materials at different times, (B) are wound area trace analysis (from left to right, groups one to five), and (C) are wound healing rate statistics. The figure shows that the wound area of ​​each group gradually decreased over time. The wound treated with CS / SD / GL hydrogel healed the fastest, while the wound treated with 0.9wt% saline healed more slowly. On day 14 of treatment, except for the group treated with 0.9wt% saline, the scabs on the wounds of the other groups fell off naturally. The wounds treated with ofloxacin hydrogel (positive control) and CS / SD / GL hydrogel had the smallest scab areas.

[0111] Mice were euthanized on days 7 and 14 of treatment. Skin around the wound was collected and homogenized in a tissue homogenizer with 1 mL of physiological saline. The homogenate was then diluted several times, and 100 μL was added to bacterial culture medium and spread evenly. The medium was then incubated at 37°C for 18 hours. The results were recorded by photographing and counting bacterial colonies. The results are as follows: Figure 13 As shown in the figure, (A) is a colony photograph, and (B) is the colony count result. It can be seen that after treatment with CS / SD / GL hydrogel, the number of Staphylococcus aureus colonies was significantly reduced, achieving the same effect as the commercially available antibacterial hydrogel ofloxacin. Simultaneously, the number of colonies at the wound site treated with CS / SD hydrogel was lower than that treated with GL, which is consistent with the wound healing status. The results indicate that CS / SD / GL hydrogel can significantly promote wound healing.

[0112] pH changes during skin wound healing are caused by a variety of factors, including inflammatory responses, cell metabolism, and the external environment. pH is a key indicator of wound condition, closely related to many physiological processes, especially bacterial infection defense and angiogenesis. For normal skin or healing wounds, the pH is typically in a slightly acidic range, between 4 and 6. This slightly acidic environment is crucial for wound healing because it inhibits the growth of harmful bacteria while promoting normal cell repair. In cases of bacterial infection, the pH around the wound tends to rise. Before establishing a mouse model, the pH of normal skin was measured using a portable pH meter. After successful model establishment, the pH of the wound skin was measured again using the pH meter. Mice were randomly grouped, and pH changes were monitored in each group on days 0, 1, 2, 3, 7, 10, and 14 of treatment. The results are as follows: Figure 14 As shown, the pH value of normal mice before wound modeling is approximately 6.25. After bacterial infection, the wound pH value rises sharply to around 8.0, possibly because Staphylococcus aureus decomposes urea to produce ammonia, thus increasing the pH value of the skin wound. During treatment, the wound pH value decreases due to inflammation associated with wound healing, which is conducive to wound remodeling. As wound healing progresses, the pH value around the wound gradually returns to normal after 14 days of treatment.

[0113] Mice were euthanized on days 3, 7, and 14 of treatment, and skin tissue approximately 1 cm in diameter was excised around the wound. This tissue was fixed in a tissue fixation solution, then embedded in paraffin to prepare tissue sections for histological analysis using H&E staining. Results are as follows: Figure 15As shown in the figure, the white dashed line represents the boundary between the epithelium and dermis, the red arrows represent inflammatory cells, the black arrows represent fibroblasts, the brown arrows represent capillaries, and the green arrows represent hair follicles. The scale bar is 50 μm. The figure shows that on day 3 of treatment, new granulation tissue began to regenerate, and all groups exhibited significant inflammation with abundant inflammatory cell infiltration and the production of numerous fibroblasts, accelerating wound healing. On day 7, the negative control group still showed inflammation, while the inflammatory response in the other groups was not significant, accompanied by the formation of hair follicles and capillaries. The epidermis began to form in the positive control group and the CS / SD / GL groups, but the connection between the epidermis and dermis was not strong and easily separated. On day 14 of treatment, the inflammation in all groups decreased, and the inflammatory cells basically disappeared. During this process, a certain number of hair follicles were observed, indicating that a structure with skin characteristics had initially formed at the wound site. The connective tissue of the dermis was relatively mature, and a large number of hair follicles and sebaceous glands grew there. In addition, the dermis was accompanied by the formation of numerous new blood vessels. In comparison, the positive control group and the CS / SD / GL group showed more significant wound healing, with near-complete wound healing, exhibiting continuous and intact epidermis, and more developed granulation tissue. Simultaneously, the wounds treated in the positive control group and the CS / SD / GL group also demonstrated good therapeutic effects in regenerating skin appendages (such as hair follicles). Therefore, CS / SD / GL hydrogel has potential application value as a wound dressing.

[0114] The expression of inflammatory factors TNF-α and IL-6 during wound healing reflects the level of inflammation in the wound microenvironment. Immunohistochemical staining was used to assess their levels. Mice were euthanized on days 3, 7, and 14 of treatment, and their skin tissues were collected for immunohistochemical staining analysis. The staining results of TNF-α and IL-6 are as follows: Figure 16 As shown in (A) and (C), the inflammatory expression in all groups decreased with increasing treatment time. Compared with the negative control group, the expression of TNF-α and IL-6 in CS / SD / GL was lower than that in GL and CS / SD. Quantitative analysis of the staining results was then performed, and the results of TNF-α and IL-6 content analysis are shown below. Figure 16 As shown in (B) and (D) (*P<0.05, **P<0.01, ***P<0.001). From Figure 16 As can be seen, the levels of TNF-α and IL-6 in CS / SD / GL were lower than those in other groups, consistent with wound healing, indicating that the addition of GL can enhance the anti-inflammatory activity of the hydrogel. This further effectively inhibits the expression of inflammatory factors in wound tissue, thereby accelerating wound healing.

[0115] Neovascularization plays a crucial role in wound healing; therefore, immunofluorescence staining was performed on vascular endothelial cell markers. CD31 is a core marker of endothelial cells and is used in vascular-related studies; α-SMA is a key marker for smooth muscle and myofibroblasts, visualizing the blood vessel wall. On day 14 of treatment, immunofluorescence staining was performed on newly formed skin to analyze the levels of α-SMA and CD31, comprehensively assessing the regeneration of neovascularization in granulation tissue. The staining results are as follows: Figure 17 As shown in (A) (scale bar 20 μm, Merge plot combines α-SMA and CD31), except for the negative control group, all other groups significantly promoted angiogenesis on day 14. The fluorescence expression of α-SMA and CD31 was strongest in the CS / SD / GL group, followed by the positive control group and the CS / SD group, and weakest in the negative control group. The fluorescence expression results of α-SMA and CD31 were quantitatively determined by calculating the relative fluorescence area of ​​positive expression, as shown in Figure (A). Figure 17 As shown in (B) and (C), the CS / SD / GL group exhibited the highest levels of α-SMA and CD31 fluorescence expression, indicating increased angiogenesis in the skin tissue. Therefore, GL-loaded CS / SD hydrogels can promote bacterial wound angiogenesis by modulating α-SMA and CD31 levels, thereby accelerating wound healing.

[0116] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A method for the preparation of a cyclodextrin-antibacterial hydrogel capable of accelerating wound healing, characterized by, Includes the following steps: A hydrophobic drug with antibacterial and anti-inflammatory effects is mixed with a solution of octa-[6-deoxy-(sodium 3-mercaptopropionate)]-γ-cyclodextrin to obtain a cyclodextrin inclusion complex solution; the cyclodextrin inclusion complex solution is then mixed with a chitosan solution to obtain a mixed solution; NaHCO3 solution is added to the mixed solution to adjust the pH to 5.8-6.5, and the mixture is allowed to stand for reaction to obtain the cyclodextrin antibacterial hydrogel that can accelerate wound healing; The mass ratio of the hydrophobic drug with antibacterial and anti-inflammatory effects to the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin contained in the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin solution is 1:1.25-10. The mass ratio of octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin in the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin solution to the chitosan in the chitosan solution is 1:5-50. The concentration of the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin solution is 5-20 mg / mL; The concentration of the chitosan solution is 40-60 mg / mL.

2. The method for preparing the cyclodextrin antibacterial hydrogel capable of accelerating wound healing as described in claim 1, characterized in that, The hydrophobic drug with antibacterial and anti-inflammatory effects is a pentacyclic triterpenoid compound.

3. The method for preparing the cyclodextrin antibacterial hydrogel capable of accelerating wound healing as described in claim 2, characterized in that, The pentacyclic triterpenoids include glycyrrhizic acid, glycyrrhetinic acid, ursolic acid, or oleanolic acid.

4. The method for preparing the cyclodextrin antibacterial hydrogel capable of accelerating wound healing as described in claim 1, characterized in that, The static reaction is carried out at a temperature of 0-40℃ for a time of 36-72 hours.

5. The method for preparing the cyclodextrin antibacterial hydrogel capable of accelerating wound healing as described in claim 1, characterized in that, The solvent for the octa-[6-deoxy-(3-mercaptopropionic acid sodium)]-γ-cyclodextrin solution includes water; And / or, the solvent of the chitosan solution includes an acid solution.

6. A cyclodextrin antibacterial hydrogel capable of accelerating wound healing prepared by a method according to any one of claims 1-5.

7. The use of the cyclodextrin antibacterial hydrogel as described in claim 6, capable of accelerating wound healing, in the preparation of a medicament or dressing for accelerating wound healing.

8. A medicine or dressing for accelerating wound healing, characterized in that, Includes the cyclodextrin antibacterial hydrogel of claim 6 that can accelerate wound healing.

Citation Information

Patent Citations

  • Method for preparing biodegradable drug loading in-situ gel

    CN107625726A

  • Self-healing multi-bridging network chitosan derivatization hydrogel and preparation method thereof

    CN111484634A